Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme

TEKCAN, ESRA; tural, sengul

doi:10.5336/pharmsci.2022-90847

Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme

Esra TEKCAN, (Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Tıbbi Biyoloji ABD, Samsun, Türkiye)

Şengül TURAL (Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Tıbbi Biyoloji Anabilim Dalı, Samsun, Türkiye)

Literatür Eczacılık Bilimleri Dergisi

6 3

Yıl: 2022 Cilt: 11 Sayı: 3 Sayfa Aralığı: 213 - 220 Metin Dili: Türkçe DOI: 10.5336/pharmsci.2022-90847 İndeks Tarihi: 18-05-2023

Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme

Öz:

Farmakogenomik, ilaç tedavisine yanıtın bireyler arası farklılık göstermesi ve bu değişken ilaç yanıtlarının altında yatan genetik me- kanizmaların anlaşılmasına dayanır. Tedavide aynı ilacın aynı dozu- nun, bir grup hastada iyi yanıt oluşturabilirken, diğer bir grupta yeterli yanıt vermemesi, farklı bir grupta da ciddi yan etkilere ve hatta ölüm- lere neden olabilmesi mümkündür. Bu nedenle ilaç yan ıtlarında bi- reyler aras ı farklılıklara belirgin şekilde katk ıda bulunan DNA varyantlarının tanımlanması, tedavilerin etkinliğini artıracak ve ilaç- ların olumsuz yan etkilerinin oranını azaltacaktır. Genom dizilimi ve mutasyon analizi farmakogenomikte çok önemli araçlardır. Farmako- genomik, hem hastan ın hem de tümörün genomunun ara ştırılmasını içerir, çünkü her ikisindeki varyasyonlar ın kanser önleyici ilacın ta- şınması, dışarı akışı, alıkonması ve penetrasyonu üzerinde bir etkisi olduğu gözlemlenmiştir. İlaç yanıtının, reçete edilen ilaçların farma- kokinetik ve farmakodinamik özelliklerine ve ilaç metabolize eden enzimler ve taşıyıcılardaki bireysel hasta polimorfizmlerine bağlı ol- duğu bilinmektedir. Bu derleme, ilaç metabolize eden enzimlerdeki polimorfizmlerin ilaç yanıtları üzerindeki etkisine odaklanmaktadır. Antikanser ilaçlar, genellikle çok dar bir terapötik indekse sahiptir; bu nedenle hastayı hayatı tehdit eden toksisite riskine sokmadan mak- simum fayday ı elde etmek için uygun dozlar ın kullan ılması çok önemlidir. Ancak hedef proteinleri ve ilaç metabolize eden enzimleri kodlayan genlerdeki spesifik polimorfizmlerin kal ıtımı nedeniyle uygun dozun ayarlanması o kadar kolay değildir. Bu derleme, bu tür polimorfizmlerin birkaç örne ğini ve bunlar ın tedaviye yan ıt üzerin- deki etkisini sunmaktadır.

Anahtar Kelime:

Pharmacogenetics in Cancer Drugs: Traditional Review

Öz:

Pharmacogenomics is based on the interindividual vari- ation in response to drug therapy and the understanding of the genetic mechanisms underlying these variable drug responses. In the treat- ment, it is possible that the same dose of the same drug may cause a good response in one group of patients, while it may not respond ad- equately in another group, and it may cause serious side effects and even death in another group. Therefore, identifying DNA variants that significantly contribute to interindividual differences in drug re- sponses will increase the efficacy of treatments and reduce the rate of adverse side effects of drugs. Genome sequencing and mutation anal- ysis are very important tools in pharmacogenomics. Pharmacoge- nomics involves investigating the genome of both the patient and the tumor, as variations in both have been observed to have an effect on the transport, efflux, retention and penetration of the anticancer drug. It is known that drug response depends on the pharmacokinetic and pharmacodynamic properties of drugs and individual patient poly- morphisms in drug metabolizing enzymes and transporters. This re- view considers the impact of existing polymorphisms in drug metabolizing enzymes on drug responses. Anticancer drugs often have a very narrow therapeutic index; therefore, it is very important to use appropriate doses to obtain maximum benefit without putting the patient at risk of life-threatening toxicity. However, due to the in- heritance of specific polymorphisms in genes encoding target pro- teins and drug metabolizing enzymes, it isn’t so easy to adjust the appropriate dose. This review presents several examples of such poly- morphisms and their impact on treatment response.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. ahmed s, zhou z, zhou J, Chen sQ. pharmacogenomics of drug me- tabolizing enzymes and transporters: relevance to precision medicine. genomics proteomics Bioinformatics. 2016;14(5):298-313. [Crossref] [pubMed] [pMC]
2. aboul-soud MaM, alzahrani aJ, Mahmoud a. Decoding variants in drug- metabolizing enzymes and transporters in solid tumor patients by whole- exome sequencing. saudi J Biol sci. 2021;28(1):628-34. [Crossref] [pubMed] [pMC]
3. Roden DM, George aL Jr. The genetic basis of variability in drug re- sponses. Nat Rev Drug Discov. 2002;1(1):37-44. [Crossref] [pubMed]
4. Meyer Ua, zanger UM, schwab M. Omics and drug response.annu Rev pharmacol Toxicol. 2013;53:475-502. [Crossref] [pubMed]
5. Franczyk B, Rysz J, Gluba-Brzózka a. pharmacogenetics of drugs used in the treatment of cancers. Genes (Basel). 2022;13(2):311. [Crossref] [pubMed] [pMC]
6. Li J, Bluth MH. pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. pharmgenomics pers Med. 2011;4:11-33. [Crossref] [pubMed] [pMC]
7. Ratain MJ, plunkett WK Jr. principles of pharmacokinetics. In: Holland- Frei Cancer Medicine. 6th ed. Kufe DW, pollock RE, Weichselbaum RR, Bast RC, Gansler Ts, Holland JF, et al, eds. BC Decker: Hamilton (ON), Canada, 2003 [accessed on 10 November 2021]. available from: [Link]
8. amstutz U, Henricks LM, Offer sM, Barbarino J, schellens JHM, swen JJ, et al. Clinical pharmacogenetics Implementation Consortium (CpIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin pharmacol Ther. 2018;103(2):210-6. [Crossref] [pubMed] [pMC]
9. soong R, shah N, salto-Tellez M, Tai BC, soo Ra, Han HC, et al. prog- nostic significance of thymidylate synthase, dihydropyrimidine dehydro- genase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemother- apy. ann Oncol. 2008;19(5):915-9. [Crossref] [pubMed] [pMC]
10. Desilets a, McCarvill W, aubin F, Bahig H, Ballivy O, Charpentier D, et al. Upfront DpYD genotyping and toxicity associated with fluoropyrimi- dine-based concurrent chemoradiotherapy for oropharyngeal carcino- mas: a work in progress. Curr Oncol. 2022;29(2):497-509. [Crossref] [pubMed] [pMC]
11. Morel a, Boisdron-Celle M, Fey L, soulie p, Craipeau MC, Traore s, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-904. [Crossref] [pubMed]
12. Lee W, Lockhart aC, Kim RB, Rothenberg ML. Cancer pharmacoge- nomics: powerful tools in cancer chemotherapy and drug development. Oncologist. 2005;10(2):104-11. [Crossref] [pubMed]
13. saltz LB, Cox JV, Blanke C, Rosen Ls, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study Group. N Engl J Med. 2000;343(13):905-14. [Crossref] [pubMed]
14. zanger UM, schwab M. Cytochrome p450 enzymes in drug metabo- lism: regulation of gene expression, en zyme activities, and impact of genetic variation. pharmacol Ther. 2013;138(1):103-41. [Crossref] [pubMed]
15. Gao Y, Li W, Chen J, Wang X, Lv Y, Huang Y, et al. pharma- cometabolomic prediction of individual differences of gastrointestinal tox- icity complicating myelosuppression in rats induced by irinotecan. acta pharm sin B. 2019;9(1):157-66. [Crossref] [pubMed] [pMC]
16. Mathijssen RH, van alphen RJ, Verweij J, Loos WJ, Nooter K, stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CpT-11). Clin Cancer Res. 2001;7(8):2182-94. [pubMed]
17. Wasserman E, Myara a, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, et al. severe CpT-11 toxicity in patients with Gilbert's syndrome: two case reports. ann Oncol. 1997;8(10):1049-51. [Crossref] [pubMed]
18. Wang Y, shen L, Xu N, Wang JW, Jiao sC, Liu zY, et al. UGT1a1 pre- dicts outcome in colorectal cancer treated with irinotecan and fluo- rouracil. World J Gastroenterol. 2012;18(45):6635-44. [Crossref] [pubMed] [pMC]
19. Beutler E, Gelbart T, Demina a. Racial variability in the UDp-glucurono- syltransferase 1 (UGT1a1) promoter: a balanced polymorphism for reg- ulation of bilirubin metabolism? proc Natl acad sci U s a. 1998;95(14):8170-4. [Crossref] [pubMed] [pMC]
20. Innocenti F, Grimsley C, Das s, Ramírez J, Cheng C, Kuttab-Boulos H, et al. Haplotype structure of the UDp-glucuronosyltransferase 1a1 pro- moter in different ethnic groups. pharmacogenetics. 2002;12(9):725-33. [Crossref] [pubMed]
21. Innocenti F, Undevia sD, Iyer L, ChenpX, Das s, Kocherginsky M, et al. Genetic variants in the UDp-glucuronosyltransferase 1a1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004;22(8):1382-8. [Crossref] [pubMed]
22. Kim TW, Innocenti F. Insights, challenges, and future directions in irino- genetics. Ther Drug Monit. 2007;29(3):265-70. [Crossref] [pubMed]
23. parte p, Kupfer D. Oxidation of tamoxifen by human flavin-containing monooxygenase (FMO) 1 and FMO3 to tamoxifen-N-oxide and its novel reduction back to tamoxifen by human cytochromes p450 and hemoglobin. Drug Metab Dispos. 2005;33(10):1446-52. [Crossref] [pubMed]
24. Desta z, Ward Ba, soukhova NV, Flockhart Da. Comprehensive evalu- ation of tamoxifen sequential biotransformation by the human cy- tochrome p450 system in vitro: prominent roles for CYp3a and CYp2D6. J pharmacol Exp Ther. 2004;310(3):1062-75. [Crossref] [pubMed]
25. Crewe HK, Notley LM, Wunsch RM, Lennard Ms, Gillam EM. Metabo- lism of tamoxifen by recombinant human cytochrome p450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002;30(8):869-74. [Crossref] [pubMed]
26. Mürdter TE, schroth W, Bacchus-Gerybadze L, Winter s, Heinkele G, simon W, et al; German Tamoxifen and aI Clinicians Group, Eichelbaum M, schwab M, Brauch H. activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin pharmacol Ther. 2011;89(5):708-17. [Crossref] [pubMed]
27. Jin Y, Desta z, stearns V, Ward B, Ho H, Lee KH, et al. CYp2D6 geno- type, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-9.[Crossref] [pubMed]
28. Madlensky L, Natarajan L, Tchu s, pu M, Mortimer J, FlattsW, et al. Ta- moxifen metabolite concentrations, CYp2D6 genotype, and breast can- cer outcomes. Clin pharmacol Ther. 2011;89(5):718-25. [Crossref] [pubMed] [pMC]
29. Higgins MJ, stearns V. CYp2D6 polymorphisms and tamoxifen metab- olism: clinical relevance. Curr Oncol Rep. 2010;12(1):7-15. [Crossref] [pubMed]
30. schroth W, Goetz Mp, Hamann U, Fasching pa, schmidt M, Winter s, et al. association between CY p2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JaMa. 2009;302(13):1429-36. [Crossref] [pubMed] [pMC]
31. Bonanni B, Macis D, Maisonneuve p, Johansson H a, Gucciardo G, Oliviero p, et al. polymorphism in the CY p2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Ta- moxifen Trial. J Clin Oncol. 2006;24(22):3708-9; author reply 3709. [Crossref] [pubMed]
32. Goetz Mp, Rae JM, suman VJ, safgren sL, ames MM, Visscher DW, et al. pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-8. [Crossref] [pubMed]
33. Goetz Mp, Knox sK, suman VJ, Rae JM, safgren sL, ames MM, et al. The impact of cytochrome p450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113-21. [Crossref] [pubMed]
34. zembutsu H, Nakamura s, akashi-Tanaka s, Kuwayama T, Watanabe C, Takamaru T, et al. significant effect of polymorphisms in CYp2D6 on re- sponse to tamoxifen therapy for breast cancer: a prospective multicen- ter study. Clin Cancer Res. 201;23(8):2019-26. [Crossref] [pubMed]
35. Teh LK, Mohamed NI, salleh Mz, Rohaizak M, shahrun Ns, saladina JJ, et al. The risk of recurrence in breast cancer patients treated with ta- moxifen: polymorphisms of CY p2D6 and aBCB1. aaps J. 2012;14(1):52-9. [Crossref] [pubMed] [pMC]
36. Lei L, Wang X, Wu XD, Wang z, Chen zH, zheng YB, et al. association of CY p2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population. am J Transl Res. 2016;8(8):3585-92. [pubMed] [pMC]
37. Franca R, zudeh G, pagarin s, Rabusin M, Lucafò M, stocco G, et al. pharmacogenetics of thiopurines. Cancer Drug Resist. 2019;2(2):256- 70. [pubMed] [pMC]
38. Otterness D, szumlanski C, Lennard L, Klemetsdal B,aarbakke J, park- Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin pharmacol Ther. 1997;62(1):60-73. [Crossref] [pubMed]
39. Innocenti F, Iyer L, Ratain MJ. pharmacogenetics: a tool for individual- izing antineoplastic therapy. Clin pharmacokinet. 2000;39(5):315-25. [Crossref] [pubMed]
40. Lennard L, Gibson BE, Nicole T, Lilleyman J s. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treat- ment for acute lymphoblastic leukaemia.arch Dis Child. 1993;69(5):577- 9. [Crossref] [pubMed] [pMC]
41. Evans WE, Hon YY, Bomgaars L, Coutre s, Holdsworth M, Janco R, et al. preponderance of thiopurine s-methyltransferase deficiency and het- erozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001;19(8):2293-301. [Crossref] [pubMed]
42. Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, pui CH, et al. Molecular diagnosis of thiopurines-methyltransferase deficiency: ge- netic basis for azathioprine and mercaptopurine intolerance. ann Intern Med. 1997;126(8):608-14. [Crossref] [pubMed]
43. Maitland ML, Vasisht K, Ratain MJ. TpMT, UGT1a1 and DpYD: geno- typing to ensure safer cancer therapy? Trends pharmacol sci. 2006;27(8):432-7. [Crossref] [pubMed]
44. Diekstra MH, Fritsch a, Kanefendt F, swen JJ, Moes D, sörgel F, et al. population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib-treated cancer. C pT pharmacometrics syst pharmacol. 2017;6(9):604-13. [Crossref] [pubMed] [pMC]
45. Teo YL, Wee HL, Chue Xp, Chau NM, Tan MH, Kanesvaran R, et al. Ef- fect of the CYp3a5 and aBCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in asian patients. pharma- cogenomics J. 2016;16(1):47-53. [Crossref] [pubMed]
46. Balram C, zhou Q, Cheung YB, Lee EJ. CY p3a5*3 and *6 single nu- cleotide polymorphisms in three distinct asian populations. Eur J Clin pharmacol. 2003;59(2):123-6. [Crossref] [pubMed]
47. Numakura K, Tsuchiya N, Kagaya H, Takahashi M, Tsuruta H, Inoue T, et al. Clinical effects of single nucleotide polymorphisms on drug-re- lated genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib. anticancer Drugs. 2017;28(1):97-103. [Crossref] [pubMed]
48. paragliola RM, Torino F, papi G, Locantore p, pontecorvi a, Corsello sM. Role of mitotane in adrenocortical carcinoma-review and state of the art. Eur Endocrinol. 2018;14(2):62-6. [Crossref] [pubMed] [pMC]
49. arshad U, Taubert M, Kurlbaum M, Frechen s, Herterich s, Megerle F, et al. Enzyme autoinduction by mitotane supported by population phar- macokinetic modelling in a large cohort of adrenocortical carcinoma pa- tients. Eur J Endocrinol. 2018;179(5):287-97. [Crossref] [pubMed]
50. Hecht M, Veigure R, Couchman L, s Barker CI, standing JF, Takkis K, et al. Utilization of data below the analytical limit of quantitation in phar- macokinetic analysis and modeling: promoting interdisciplinary debate. Bioanalysis. 2018;10(15):1229-48. [Crossref] [pubMed]
51. Mornar a, sertić M, Turk N, Nigović B, Koršić M. simultaneous analysis of mitotane and its main metabolites in human blood and urine samples by spE-HpLC technique. Biomed Chromatogr. 2012;26(11):1308-14. [Crossref] [pubMed]
52. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L,sangkuhl K, Thorn CF, et al. pharmacogenomics knowledge for personalized medicine. Clin pharmacol Ther. 2012;92(4):414-7. [Crossref] [pubMed] [pMC]
53. Nath a, Wang J, stephanie Huang R. pharmacogenetics and pharma- cogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia. Mol Diagn Ther. 2017;21(6):621-31. [Crossref] [pubMed] [pMC]
54. ankathil R, zian aa, Nizam zM, azlan H, Baba aa. p0223 CYp3a4*18 and CY p3a5*3 gene polymorphisms and imatinib resistance in Malaysian patients with chronic myeloid leukaemia. Eur J Cancer. 2014;50(4):e71-2. [Crossref]
55. Filppula aM, Neuvonen M, Laitila J, NeuvonenpJ, Backman JT. autoin- hibition of CY p3a4 leads to important role of CY p2C8 in imatinib me- tabolism: variability in CYp2C8 activity may alter plasma concentrations and response. Drug Metab Dispos. 2013;41(1):50-9. [Crossref] [pubMed]
56. Maddin N, Husina, Gan sH, aziz Ba, ankathil R. Impact of CYp3a4*18 and CYp3a5*3 polymorphisms on imatinib mesylate response among chronic myeloid leukemia patients in Malaysia. Oncol Ther. 2016;4(2):303-14. [Crossref] [pubMed] [pMC]

APA	TEKCAN E, tural s (2022). Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. , 213 - 220. 10.5336/pharmsci.2022-90847
Chicago	TEKCAN ESRA,tural sengul Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. (2022): 213 - 220. 10.5336/pharmsci.2022-90847
MLA	TEKCAN ESRA,tural sengul Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. , 2022, ss.213 - 220. 10.5336/pharmsci.2022-90847
AMA	TEKCAN E,tural s Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. . 2022; 213 - 220. 10.5336/pharmsci.2022-90847
Vancouver	TEKCAN E,tural s Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. . 2022; 213 - 220. 10.5336/pharmsci.2022-90847
IEEE	TEKCAN E,tural s "Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme." , ss.213 - 220, 2022. 10.5336/pharmsci.2022-90847
ISNAD	TEKCAN, ESRA - tural, sengul. "Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme". (2022), 213-220. https://doi.org/10.5336/pharmsci.2022-90847

APA	TEKCAN E, tural s (2022). Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi, 11(3), 213 - 220. 10.5336/pharmsci.2022-90847
Chicago	TEKCAN ESRA,tural sengul Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi 11, no.3 (2022): 213 - 220. 10.5336/pharmsci.2022-90847
MLA	TEKCAN ESRA,tural sengul Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi, vol.11, no.3, 2022, ss.213 - 220. 10.5336/pharmsci.2022-90847
AMA	TEKCAN E,tural s Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi. 2022; 11(3): 213 - 220. 10.5336/pharmsci.2022-90847
Vancouver	TEKCAN E,tural s Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme. Literatür Eczacılık Bilimleri Dergisi. 2022; 11(3): 213 - 220. 10.5336/pharmsci.2022-90847
IEEE	TEKCAN E,tural s "Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme." Literatür Eczacılık Bilimleri Dergisi, 11, ss.213 - 220, 2022. 10.5336/pharmsci.2022-90847
ISNAD	TEKCAN, ESRA - tural, sengul. "Kanser İlaçlarında Farmakogenetik: Geleneksel Derleme". Literatür Eczacılık Bilimleri Dergisi 11/3 (2022), 213-220. https://doi.org/10.5336/pharmsci.2022-90847